Protagonist Therapeutics/$PTGX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Ticker
$PTGX
Sector
Primary listing
Employees
128
Headquarters
Website
PTGX Metrics
BasicAdvanced
$5.6B
124.77
$0.72
2.20
-
Price and volume
Market cap
$5.6B
Beta
2.2
52-week high
$93.25
52-week low
$33.70
Average daily volume
946K
Financial strength
Current ratio
13.048
Quick ratio
12.938
Long term debt to equity
1.32
Total debt to equity
1.665
Profitability
EBITDA (TTM)
20.03
Gross margin (TTM)
100.00%
Net profit margin (TTM)
21.94%
Operating margin (TTM)
9.09%
Effective tax rate (TTM)
4.50%
Revenue per employee (TTM)
$1,630,000
Management effectiveness
Return on assets (TTM)
1.82%
Return on equity (TTM)
7.80%
Valuation
Price to earnings (TTM)
124.768
Price to revenue (TTM)
27.122
Price to book
8.69
Price to tangible book (TTM)
8.69
Price to free cash flow (TTM)
89.064
Free cash flow yield (TTM)
1.12%
Free cash flow per share (TTM)
1.009
Growth
Revenue change (TTM)
-35.39%
Earnings per share change (TTM)
-73.17%
3-year revenue growth (CAGR)
81.15%
3-year earnings per share growth (CAGR)
-35.37%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
PTGX News
AllArticlesVideos
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Accesswire3 weeks ago
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
Accesswire3 weeks ago
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $5.6B as of November 27, 2025.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 124.77 as of November 27, 2025.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of November 27, 2025.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.